Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both
Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM. Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both. New England Journal Of Medicine 2003, 349: 1893-1906. PMID: 14610160, DOI: 10.1056/nejmoa032292.Peer-Reviewed Original ResearchConceptsCaptopril groupValsartan groupMyocardial infarctionCardiovascular eventsAdverse eventsHeart failureMost drug-related adverse eventsDrug-related adverse eventsLeft ventricular systolic dysfunctionAngiotensin receptor blocker valsartanAngiotensin converting enzyme (ACE) inhibitorsEnd pointMyocardial Infarction ComplicatedNonfatal cardiovascular eventsDouble-blind trialPrimary end pointVentricular systolic dysfunctionComposite end pointLeft ventricular dysfunctionPopulation of patientsACE inhibitor captoprilAcute myocardial infarctionAdditional therapyCardiovascular morbidityRenal dysfunction